What are you looking for today?

Hill, Rebecca M., Kuijper, Sanne, Lindsey, Janet, Schwalbe, Ed C., Barker, Karen, Boult, Jessica, Williamson, Daniel, Ahmad, Zai, Hallsworth, Albert, Ryan, Sarra, Poon, Evon, Robinson, Simon, Ruddle, Ruth, Raynaud, Florence, Howell, Louise, Kwok, Colin, Joshi, Abhijit, Nicholson, Sarah, Crosier, Stephen, Wharton, Stephen, Jacques, Tom, Robson, Keith, Michalski, Antony, Hargrave, Darren, Pizer, Barry, Bailey, Simon, Swartling, Fredrik J., Petrie, Kevin, Weiss, William A., Chesler, Louis and Clifford, Steve (2014) Abstract LB-201: MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically. Cancer Research, 74 (19_Sup). LB-201. ISSN 0008-5472

Full text not available from this repository. (Request a copy)

Abstract

Abstract

Disease recurrence following multi-modal therapy is the single most adverse event in medulloblastoma (MB). Currently >90% of relapsing patients die, accounting for ∼10% of childhood cancer deaths. MB is heterogeneous at diagnosis, comprising four molecular subgroups with distinct clinicopathological and molecular features and outcomes. The relevance of these features at relapse is unknown, making characterisation, modelling and targeted therapy of relapse biology essential to improve outcomes. However, relapsed MBs are not routinely biopsied in clinical practice.
We undertook a first comprehensive investigation of the molecular, clinical and pathological features of 29 relapsed MBs and paired tumour samples taken at diagnosis, including the assessment of features with established significance at diagnosis (e.g. chromosome 17 and TP53 pathway status, MYC family (MYC, MYCN) gene amplification, polyploidy, CTNNB1 mutation and molecular subgroup status). Molecular subgroup was concordant at diagnosis and relapse, however evidence of alteration of all other features examined was found in relapsed tumours, with the majority of changes (30/44) representing acquired high-risk events. Most notably, MYC family gene amplifications and TP53 pathway defects commonly emerged in combination at relapse following conventional multimodal treatment (P=0.02, 7/22, 32%) and predicted rapid progression to death (P=0.016).
These observations suggested aberrant activation of MYC family genes synergizes with TP53 inactivation in the genesis of biologically aggressive MB. To investigate any such relationship, we examined Trp53 status in our transgenic mouse model of spontaneously-arising MYCN-driven MB (GTML; Glt1-tTA/TRE-MYCN-Luc). Somatic Trp53 mutations were found in 83% of tumors (n=10/12). Direct modelling of this interaction in GTML/Trp53KI/KI mice dramatically enhanced MB formation with 100% penetrance (43/43, median survival 47 days) in GTML/Trp53KI/KI versus 6% (3/50) in GTML; P<0.0001), faithfully mimicked clinicopathological characteristics of TP53-MYC family gene-associated relapsed human tumors, and validated the essential role of TP53 in potentiating the growth of MYCN-driven MB. Finally, therapeutic inhibition of Aurora-A kinase using MLN8237 in these tumours, and in derived neurospheres in vitro, promoted degradation of MYCN, reduced tumor growth and prolonged survival.
In summary, while subgroup status remains stable, MBs display altered molecular, pathological and clinical features at relapse, and the emergence of combined TP53-MYC family gene defects is common following conventional therapy. Their association with rapid demise, coupled with their biological validation as driving and therapeutically exploitable events in a novel mouse MB model, strongly support further investigation and routine biopsy of relapse disease to drive future individualised therapeutic strategies.

Item Type: Article
Depositing User: Kevin Petrie
URI: https://sure.sunderland.ac.uk/id/eprint/15811

Further Details

More Information

Depositing User

Identifiers

Item ID
15811
Identification Number
ISSN
0008-5472

Users with ORCIDS

ORCID for Kevin Petrie

Catalogue record

Date Deposited
22 Mar 2023 14:27
Last Modified
04 Jun 2025 16:18

Contributors

Author
Rebecca M. Hill
Author
Sanne Kuijper
Author
Janet Lindsey
Author
Ed C. Schwalbe
Author
Karen Barker
Author
Jessica Boult
Author
Daniel Williamson
Author
Zai Ahmad
Author
Albert Hallsworth
Author
Sarra Ryan
Author
Evon Poon
Author
Simon Robinson
Author
Ruth Ruddle
Author
Florence Raynaud
Author
Louise Howell
Author
Colin Kwok
Author
Abhijit Joshi
Author
Sarah Nicholson
Author
Stephen Crosier
Author
Stephen Wharton
Author
Tom Jacques
Author
Keith Robson
Author
Antony Michalski
Author
Darren Hargrave
Author
Barry Pizer
Author
Simon Bailey
Author
Fredrik J. Swartling
Author
William A. Weiss
Author
Louis Chesler
Author
Steve Clifford

University Divisions

Subjects

Actions (login required)

View Item (Repository Staff Only)